{
  "source": "PA-Notification-Weight-Loss.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1114-18\nProgram Prior Authorization/Notification - Plans with Weight Loss/Appetite\nSuppression Medication Coverage\nMedication Includes both brand and generic versions and all formulations of the\nlisted products unless otherwise noted: Weight Loss/Appetite\nSuppresion – phentermine (all brand products including Adipex-P® and\nLomaira™), benzphetamine, Contrave® (naltrexone HCl and bupropion\nHCl, diethylpropion, Imcivree® (setmelanotide), phendimetrazine, orlistat\n(Xenical®), Qsymia® (phentermine and topiramate extended-release),\nSaxenda® (liraglutide), Vykat XR™ (diazoxide choline), Wegovy®\n(semaglutide) and Zepbound™ (tirzepatide)\nP&T Approval Date 1/08, 1/2010, 1/2011, 1/2012, 11/2012, 11/2013, 11/2014, 7/2015, 9/2016,\n9/2017, 9/2018, 9/2019, 9/2020, 4/2021, 9/2021, 9/2022, 2/2023, 12/2023,\n5/2024, 7/2024, 3/2025, 5/2025, 6/2025\nEffective Date 9/1/2025\n1. Background:\nThis is an optional program that is put in place for clients or businesses that have elected to\ncover weight loss products with Prior Authorization/Notification. It is also designed to meet\nregulatory requirements for coverage of weight loss medications in California, New Mexico,\nNorth Dakota Essential Health Benefits (EHB) and New York.\nClassification BMI(kg/m2)\nUnderweight < 18.50\nNormal range 18.50 - 24.99\nOverweight ≥ 25.00\nObese ≥ 30.00\nObese class I 30.00 - 34.99\nObese class II 35.00 - 39.99\nObese class III ≥ 40.00\nSection Overview\nSection 2: General coverage criteria\nSection 3: Coverage criteria for North Dakota Fully Insured EHB (Small Group and Individual)\nPlans\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. benzphetamine, Contrave, diethylpropion, phentermine, phendimetrazine, Qsymia,\nSaxenda, Wegovy, Xenical or Zepbound (Includes both brand and generic versions\n© 2025 UnitedHealthcare Services Inc.\n1\nand all formulations of the listed products unless otherwise noted) will be approved\nbased on all of the following cr",
    " (Includes both brand and generic versions\n© 2025 UnitedHealthcare Services Inc.\n1\nand all formulations of the listed products unless otherwise noted) will be approved\nbased on all of the following criteria:\na. One of the following:\n(1) Treatment is being requested for appetite suppression or weight loss\n(2) Wegovy is being requested for risk reduction of major adverse cardiovascular\nevents with established cardiovascular disease (i.e. prior myocardial infarction,\nischemic or hemorrhagic stroke, or peripheral arterial disease)b\n(3) Zepbound is being requested for moderate to severe obstructive sleep apneac\n-AND-\nb. One of the following:\n(1) Patient is ≥ 12 years of age (for Qsymia, Saxenda, Wegovy and Xenical)\n(2) Patient is > 16 years of age (for other appetite suppressants)\n-AND-\nc. Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction,\nexercise, behavioral support, community-based program)\n-AND-\nd. One of the following:\n(1) Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th\npercentile\n-OR-\n(2) Both of the following:\n(a) BMI ≥ 27 kg/m2\n-AND-\n(b) Patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension,\ntype 2 diabetes, sleep apnea)\nbenzphetamine, diethylpropion, phendimetrazine, phentermine: Authorization will\nbe issued for 3 months.\nContrave, Qsymia or Saxenda: Authorization will be issued for 4 months.\nWegovy: Authorization will be issued for 5 months.\nXenical or Zepbound: Authorization will be issued for 6 months.\n© 2025 UnitedHealthcare Services Inc.\n2\n2. Imcivree will be approved based on all of the following criteria:\na. One of the following:\n(1) Diagnosis of obesity is due to POMC, PCSK1, or LEPR gene deficiency\nconfirmed with genetic testing interpreted as pathogenic, likely pathogenic, or of\nuncertain significance\n-OR-\n(2) Diagnosis of Bardet-Biedl syndrome\n-AND-\nb. One of the following:\n(1) Adult patient with BMI ≥ 30 kg/m2\n-OR-\n(2) Pediatric patient with weight >95th percentile for age ",
    "uncertain significance\n-OR-\n(2) Diagnosis of Bardet-Biedl syndrome\n-AND-\nb. One of the following:\n(1) Adult patient with BMI ≥ 30 kg/m2\n-OR-\n(2) Pediatric patient with weight >95th percentile for age on growth chart assessment\n-AND-\nc. Patient is currently enrolled in or has history of a weight loss management program\nAuthorization will be issued for 6 months.\n3. Vykat XR will be approved based on all of the following criteria:\na. Diagnosis of hyperphagia associated with Prader-Willi Syndrome\n-AND-\nb. Prader-Willi Syndrome is confirmed by genetic testing\n-AND-\nc. Patient is at least 4 years of age and older\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. benzphetamine Contrave, diethylpropion, phentermine, phendimetrazine, Qsymia,\nSaxenda, Wegovy, Xenical or Zepbound (Includes both brand and generic versions\nand all formulations of the listed products unless otherwise noted) will be approved\nbased on both of the following criteria:\na. One of the following:\n© 2025 UnitedHealthcare Services Inc.\n3\n(1) Weight loss of ≥ 3% of baseline body weight for Qsymia\n(2) Weight loss of ≥ 4% of baseline body weight for Saxenda\n(3) Weight loss of ≥ 5% of baseline body weight for all other appetite suppressants\n-AND-\nb. Continuation of lifestyle modification\nAuthorization for Contrave, Qsymia, Saxenda, Wegovy Xenical or Zepbound will\nbe issued for 12 months.\nAuthorization for benzphetamine, diethylpropion, phentermine or phendimetrazine\nor will be issued for 6 months.\n2. Imcivree will be approved based on one of the following criteria:\na. If on therapy for less than 12 months, documentation of a positive clinical response\nto Imcivree therapy defined as weight loss ≥5% of baseline weight\n-OR-\nb. If on therapy for ≥12 months, documentation of a positive clinical response to\nImcivree therapy defined as ≥10% weight loss from baseline\nAuthorization will be issued for 12 months.\n3. Vykat XR will be approved based on the following criterion:\na. Documentation of positive c",
    " to\nImcivree therapy defined as ≥10% weight loss from baseline\nAuthorization will be issued for 12 months.\n3. Vykat XR will be approved based on the following criterion:\na. Documentation of positive clinical response to Vykat XR therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb Refer to Nonformulary Wegovy criteria for plans that do not cover weight loss medications.\nc Refer to Nonformulary Zepbound criteria for plans that do not cover weight loss medications.\n3. Coverage Criteria for North Dakota Fully Insured EHB (Small Group and Individual)\nPlansa:\nA. Initial Authorization\n1. Wegovy or Zepbound will be approved based on all of the following criteria:\na. One of the following:\n(1) Treatment is being requested for appetite suppression or weight loss\n© 2025 UnitedHealthcare Services Inc.\n4\n(2) Wegovy is being requested for risk reduction of major adverse cardiovascular\nevents with established cardiovascular disease (i.e. prior myocardial\ninfarction, ischemic or hemorrhagic stroke, or peripheral arterial disease)b\n(3) Zepbound is being requested for moderate to severe obstructive sleep apneac\n-AND-\nb. One of the following:\n(1) Patient is ≥ 12 years of age for Wegovy\n(2) Patient is > 16 years of age for Zepbound\n-AND-\nc. Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction,\nexercise, behavioral support, community-based program)\n-AND-\nd. Body Mass Index (BMI) ≥ 40 kg/m2 or for pediatric patients a BMI > 120% of\n95th percentile\nWegovy: Authorization will be issued for 5 months.\nZepbound: Authorization will be issued for 6 months.\nB. Reauthorization\n1. Wegovy or Zepbound will be approved based on both of the following criteria:\na. Weight loss of ≥ 5% of baseline body weight\n-AND-\nb. Continuation of lifestyle modification\nAuthorization ",
    "horization\n1. Wegovy or Zepbound will be approved based on both of the following criteria:\na. Weight loss of ≥ 5% of baseline body weight\n-AND-\nb. Continuation of lifestyle modification\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb Refer to Nonformulary Wegovy criteria for plans that do not cover weight loss medications.\nc Refer to Nonformulary Zepbound criteria for plans that do not cover weight loss medications.\n4. Additional Clinical Rules:\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services Inc.\n5\n5. References:\n1. American Association of Clinical Endocrinologists and American College of\nEndocrinology Comprehensive Clinical Practice Guidelines for Medical Care of\nPatients with Obesity. Endocr Pract. 2016;22(Suppl 3).\n2. Benzphetamine [package insert]. Laurelton, NY: Epic Pharma, LLC; June 2023.\n3. Diethylpropion ER [package insert]. Congers, NY: Chartwell RX, LLC; March 2023.\n4. Phendimetrazine Slow-Release Capsules [package insert]. Langhorne, PA: Acertis\nPharmaceuticals, LLC; September 2019.\n5. Adipex-P [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; March 2024.\n6. Xenical [package insert]. Montgomery, AL: H2-Pharma, LLC; July 2024.\n7. Qsymia [package insert]. Moutain View, CA. Vivus, Inc ; September 2024.\n8. Contrave [package insert]. Brentwood, TN: Nalpropion Pharmaceuticals, LLC; May 2024.\n9. Saxenda [package insert]. Plainsboro, NJ: Novo Nordisk ; November 2024.\n10. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice\nGuideline. The Journal of Clinical Endocrinology & Metabolism 2015 100:2, 342-362\n11. AHA/ACC/TOS Prevention Guideline: 2013 AHA/ACC/TOS Guideline for the\nManagement of Overweight and Obesity in Adults: A Report to the American College of\nCardiology/American Health Association Task F",
    ". AHA/ACC/TOS Prevention Guideline: 2013 AHA/ACC/TOS Guideline for the\nManagement of Overweight and Obesity in Adults: A Report to the American College of\nCardiology/American Health Association Task Force on Practice Guidelines and The\nObesity Society. Circulation. 2014; 129:S102-138\n12. World Health Organization. (2006). Global Database on Body Mass Index. Retrieved\nfrom https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index\n13. Lomaira [package insert]. Newtown, PA: KVK-Tech, Inc. December 2023.\n14. Imcivree [package insert]. Boston, MA: Rhythm Pharmaceuticals, Inc; November 2023.\n15. Wegovy [package insert]. Plainsboro, NJ: Novo Nordisk; November 2024.\n16. Jastreboff, AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J\nMed 2022 ; 387 : 205-216.\n17. Zepbound [package insert]. Indianapolis, IN: Lilly USA, LLC ; December 2024.\n18. Grunvald E, Shah R, Hernaez R, etc al. AGA Clinical Practice Guideline on\nPharmacological Interventions for Adults with Obesity. Gastroenterology 2022;163:1198-\n1225.\n19. Vykat XR [package insert]. Redwood City, CA : Soleno Therapeutics, Inc.; March 2025.\nProgram Weight Loss/Appetite Suppression\nChange Control\nDate Change\n11/2013 Reformatted to standard and updated references. Clarified risk factors\nrequired in addition to BMI of 27-29. Removed criteria that coverage\nwould not be provided if used in combination with other weight loss\nagents. Shortened initial authorization for sympathomimetics to 3\nmonths based on PI recommendations for short-term use. Added\nreauthorization criteria for 6 months, changed initial authorization\nperiod of Xenical from 4 months to 3 months, and shortened\nreauthorization of Belviq and Xenical to 12 months for alignment with\nOptumRx.\n11/2014 Added Contrave to guideline.\n7/2015 Added Saxenda to guideline.\n© 2025 UnitedHealthcare Services Inc.\n6\n9/2016 Annual Review. Added Belviq XR to guideline. Revised authorization\nperiod for Xenical. Removed ASO from title- prog",
    "e.\n7/2015 Added Saxenda to guideline.\n© 2025 UnitedHealthcare Services Inc.\n6\n9/2016 Annual Review. Added Belviq XR to guideline. Revised authorization\nperiod for Xenical. Removed ASO from title- program will remain as\nASO option.\n9/2017 Annual Review. Added Lomaira. Updated references. Revised\nweightloss percentage for Saxenda per PI.\n9/2018 Annual Review. Updated references. .\n9/2019 Annual Review. Revised background section. Revised list of\nmodifications of weight related comorbidity.\n9/2020 Annual review. Updated references. Removed Belviq/Belviq XR.\n4/2021 Added Imcivree as in scope. Added Imcivree criteria. Updated\nreferences. Formatting changes.\n9/2021 Added Wegovy to criteria. Updated Saxenda criteria to allow for\ncoverage for 12 years and older. Updated Qsymia weight loss goal to\ngreater than 3 percent per label and changed initial authorization to 4\nmonths. Updated references.\n9/2022 Added background note that this program is intended to meet regulatory\nrequirements for coverage of weight loss medications in California,\nMaryland, New Mexico and New York. This program is replacing\npolicy P 1172-8. Changed Qsymia age requirement to 12 or older due to\nnew pediatric labeling. Updated Imcivree to include new FDA\napproved indication for Bardet-Biedl syndrome. Updated references.\n2/2023 Updated Wegovy criteria to include pediatric patients based on new\nlabeling. Added state mandate language.\n12/2023 Added Zepbound to criteria. Removed Maryland from background.\n5/2024 Removed notation that Zepbound may be excluded at launch. Added\ncoverage for secondary cardiovascular risk reduction for Wegovy.\n7/2024 Added coverage requirements for North Dakota EHB.\n3/2025 Added coverage for obstructive sleep apnea for Zepbound.\n5/2025 Updated Wegovy initial authorization duration to 5 months.\n6/2025 Added Vykat XR as in scope. Added Vykat XR criteria and updated\nprogram name to include appetite suppressants. Updated references.\nFormatting changes.\n© 2025 UnitedHealthcare Service",
    " 5 months.\n6/2025 Added Vykat XR as in scope. Added Vykat XR criteria and updated\nprogram name to include appetite suppressants. Updated references.\nFormatting changes.\n© 2025 UnitedHealthcare Services Inc.\n7"
  ]
}